問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Digestive System Department

Division of General Internal Medicine

Division of Hematology & Oncology

國立臺灣大學醫學院

Division of General Surgery

更新時間：2023-09-19

何明志Ho, Ming-Chih
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

何明志

List

41Cases

2014-04-20 - 2016-05-20

Phase II

Completed
Randomized, Open Label, Phase 2 Trial of ADI-PEG 20 plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    ADI-PEG 20

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of General Surgery

2018-03-01 - 2023-12-31

Phase III

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Atezolizumab; Bevacizumab; Sorafenib

Participate Sites
5Sites

Terminated5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2022-03-31 - 2027-12-31

Phase III

A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    DurvalumabTremelimumab

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2016-03-14 - 2017-09-07

Phase III

A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (MAGELLAN-2)

  • Condition/Disease

    Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
2Sites

Terminated2Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2023-08-01 - 2028-06-30

Others

A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Tecentriq (RO5541267) (Atezolizumab)Avastin (RO4876646) (Bevacizumab)RO7092284 (Tiragolumab)RO7247669 (PD1-LAG3)

Participate Sites
5Sites

Recruiting5Sites

2011-01-01 - 2017-12-31

Phase III

A prospective, randomized, double-blind, placebo-controlled, parallel-group, international multicenter phase III trail of PI-88 in the adjuvant treatment of subjects with hepatitis virus related hepatocellular

  • Condition/Disease

    Postoperative adjuvant therapy for hepatitis virus-related liver cancer

  • Test Drug

    PI-88 or matching placebo

Participate Sites
9Sites

Terminated9Sites

2017-12-01 - 2018-12-20

Others

A Retrospective Chart Review Study of Patients Who Previously Participated in the PATRON Phase III Trial

  • Condition/Disease

    Adjuvant treatment of Post- Resection Hepatocellular Carcinoma

  • Test Drug

    Muparfostat (PI-88)

Participate Sites
10Sites

Terminated8Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of Others-

2019-12-20 - 2024-08-16

IIT

Phase II

Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)

  • Condition/Disease

    advanced hepatocellular carcinoma (HCC)

  • Test Drug

    1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)

Participate Sites
2Sites

Recruiting2Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2016-02-01 - 2019-05-01

Phase III

A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Nivolumab/Sorafenib

Participate Sites
8Sites

Terminated7Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

彭成元
China Medical University Hospital-Taipei

未分科

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB